Is Brain a Good Journal? An Honest Assessment for 2026

Brain carries weight that newer journals simply can't match. It's the journal that published Hughlings Jackson's work on epilepsy, Henry Head's research on sensory pathways, and MacDonald Critchley's observations on parietal lobe function. When you see "Brain" in a reference list, you know the work went through serious scrutiny.

This reputation translates into real advantages for authors. Papers published in Brain get cited more often and for longer periods than comparable work in newer journals. Funding agencies recognize Brain publications as evidence of research quality. Academic promotion committees understand that getting into Brain means something.

The editorial board reflects this status. Current and former editors include some of the most respected names in neurology: Martin Rossor, Nick Fox, John Hardy, Maria Thom. These aren't just academic figureheads — they're actively involved in editorial decisions and set the journal's scientific direction.

Brain competes directly with Annals of Neurology, JAMA Neurology, and The Lancet Neurology. The Lancet Neurology generally sits higher on pure prestige metrics, but Brain often carries deeper respect among neurologists who care about mechanistic depth. Annals covers similar territory with slightly different editorial preferences, while JAMA Neurology tends to publish more clinical-practice-facing work alongside research.

What sets Brain apart is consistency. It's maintained editorial quality and scientific rigor for nearly 150 years. Editors change, research methods evolve, but the commitment to mechanistic understanding remains constant.

Brain's impact factor sits at 10.6, which places it among the top tier of neurology journals but below the very highest-impact general medical journals. That number reflects both the quality of work published and the size of the field citing it.

Here's what that 10.6 means practically: papers published in Brain get cited an average of about 11 times per year for the two years after publication. Good papers get cited much more. Mediocre papers drag the average down. The impact factor tells you about journal prestige, but your individual paper's impact depends on the quality of your specific contribution.

The acceptance rate hovers around 15%, though Brain doesn't publish exact numbers. This means roughly 85% of submitted papers get rejected. Those aren't encouraging odds, but they reflect the journal's selectivity rather than impossibility. If your paper advances mechanistic understanding of nervous system function with solid methodology, you're competing in a much smaller pool than the overall submission numbers suggest.

Understanding how to choose the right journal becomes important when facing these odds. Brain works best when your research question and methodology align with what the journal actually publishes, not when you're hoping to elevate modest findings through journal prestige.

The rejection rate breaks down predictably. About 30-40% of papers get desk-rejected without external review — usually because they don't fit Brain's scope or lack sufficient methodological rigor. Another 40-50% get rejected after peer review, typically because reviewers identify methodological problems or question the mechanistic significance. The remaining papers either get accepted (rare) or receive major revision requests (more common).

Brain's editorial process moves faster than many high-impact journals. First decisions typically come within 6-8 weeks of submission. That's quick enough to maintain momentum but slow enough for thorough review.

The process starts with editorial triage. Editors screen submissions for scope fit and basic methodological soundness before sending papers to external reviewers. About one-third of submissions get desk-rejected at this stage — usually because the research doesn't fit Brain's mechanistic focus or because obvious methodological problems make external review pointless.

Papers that clear editorial triage go to 2-3 external reviewers chosen for expertise in the specific research area. Brain's reviewer pool includes practicing neurologists, neuroscientists, and methodological experts. Reviews tend to be detailed and constructive, focusing on whether the paper actually advances mechanistic understanding rather than just documenting observations.

The editorial decision process is relatively straightforward. Papers either get rejected, accepted (rare), or receive revision requests. Revision requests usually focus on clarifying mechanistic claims, strengthening statistical analysis, or better connecting findings to clinical relevance. Authors typically get 2-3 months to revise, with revised papers going back to the same reviewers when possible.

Brain doesn't use a rounds-of-revision approach that drags on indefinitely. Most papers either get accepted after one revision or rejected if the revision doesn't address reviewer concerns adequately.

Submit to Brain if you're a clinical neurologist or neuroscientist with mechanistic insights into how the nervous system works or fails. The journal works best for researchers who can connect cellular or systems-level findings to clinical observations that matter for patient care.

Movement disorder researchers should definitely consider Brain. The journal has published foundational work on Parkinson's disease pathophysiology, Huntington's disease progression, and ataxia mechanisms. If you've got new insights into how these diseases develop or progress — whether from genetics, neuroimaging, or biomarker studies — Brain is an appropriate target.

Stroke researchers fit well when their work explains mechanism rather than just documenting outcomes. Papers that connect imaging findings to underlying pathophysiology, or that reveal how brain networks reorganize after injury, align with Brain's editorial preferences. Pure epidemiological studies or treatment comparisons without mechanistic insight fit better elsewhere.

Neurodegeneration researchers should focus on mechanism over association. If you've identified new pathways involved in Alzheimer's disease, or revealed how protein aggregation leads to neuronal dysfunction, Brain is appropriate. If you've just documented another association between biomarkers and cognitive decline, look elsewhere.

Epilepsy researchers who study seizure networks, mechanisms of epileptogenesis, or connections between genetics and seizure phenotypes should consider Brain. The journal has published important work on seizure propagation, network dynamics, and genetic causes of epilepsy syndromes.

Your methodology matters as much as your topic. Brain expects rigorous sample sizes, appropriate statistical analysis, and methods that can actually support the mechanistic claims you're making. If you're studying a rare disease, you need compelling evidence that your findings generalize beyond the specific patients studied.

The clinical relevance requirement is real but flexible. You don't need immediate therapeutic implications, but you do need plausible connections to clinical neurology. Basic neuroscience studies that reveal fundamental mechanisms of neural function can work if you can articulate why neurologists should care about the findings.

Consider Brain if practicing neurologists would cite your work when thinking about patient care, even if the clinical applications aren't immediate. Skip Brain if your work is primarily of interest to basic researchers without clear clinical connections.